Systematic Review Identifies Effective CSU Treatment Options

Chronic spontaneous urticaria (CSU) remains a treatment challenge in dermatology, with approximately one-third of patients continuing to experience symptoms despite omalizumab therapy.¹ A systematic review presented at the American Academy of Dermatology 2026 annual meeting has identified several new pharmacologic options with evidence supporting their efficacy in antihistamine-resistant disease.²

Researchers from Wake Forest University School of Medicine analyzed 16 randomized, placebo-controlled trials examining seven novel drugs for CSU across patients aged 12 to 80 years. The analysis found clear distinction between agents that demonstrated efficacy and those that did not, providing practitioners with an evidence-based framework for treatment selection in this patient population.

Efficacious Agents: Tyrosine Kinase Inhibitors

Two oral Bruton's tyrosine kinase (BTK) inhibitors emerged as effective options. Fenebrutinib, studied at 8 weeks, produced a mean reduction in the Urticaria Activity Score (UAS7) of -11.7 to -20.7 points, with 13% to 39% of patients achieving a UAS7 of 0 compared to 4% in the placebo group. Remibrutinib demonstrated greater efficacy at 12-week follow-up, with a UAS7 reduction of -15.3 to -20.2 points and 26.7% to 41.9% of patients reaching complete control. Extended data at 52 weeks showed sustained benefit, with a mean UAS7 reduction of -21.8 and 55.8% of patients achieving a score of 0.

Injectable Biologics

Among injectable agents, ligelizumab—a monoclonal antibody targeting circulating immunoglobulin E—demonstrated consistent efficacy in both adult and adolescent populations. In adults at 12 weeks, UAS7 decreased by -19.2 to -20.3 points, with 29% to 44% achieving complete control versus 0% to 8% in placebo groups. Adolescent data showed slightly lower response rates but maintained superiority over placebo. Long-term data at 52 weeks showed sustained response, with over half of adults achieving UAS7=0.

Dupilumab, an IL-4α receptor antagonist, showed differential efficacy based on prior omalizumab exposure. Patients naive to anti-IgE therapy experienced a UAS7 reduction of -20.5 points with 31.4% achieving complete control. Those with prior omalizumab exposure showed diminished but clinically meaningful response, with UAS7 reduction of -14.4 and 13% complete control.

Ineffective Agents

The review identified several agents without meaningful clinical benefit in CSU. Benralizumab, tezepelumab, quilizumab, and canakinumab all failed to demonstrate superiority over placebo in clinical efficacy, despite their success in other allergic or inflammatory conditions. These findings suggest disease-specific mechanisms not adequately targeted by these agents.

Study Quality and Clinical Implications

The systematic review noted that most included trials provided high-quality evidence by Rob2 assessment, with the majority rated at low risk of bias. Only tezepelumab and quilizumab raised some concerns regarding bias, yet the aggregate evidence quality supports confidence in the reported findings.

The heterogeneity in outcome measurement across trials—including variations in UAS7 change from baseline, proportion achieving complete control, and follow-up duration—precluded formal meta-analysis. Nevertheless, the tabulated comparisons allow clinicians to compare drug performance within similar timeframes.

Clinical Significance

These findings have immediate implications for CSU management. The efficacy of BTK inhibitors and anti-IgE/IL-4α biologics provides evidence-based alternatives for patients failing standard therapy. The 12-to-24-week efficacy windows align with typical clinical reassessment periods, and the high proportion of patients achieving complete symptom control (UAS7=0) represents a meaningful improvement in quality of life—the primary goal of CSU treatment.

For practitioners, the data suggest that treatment selection may benefit from consideration of prior omalizumab exposure, duration of disease, and patient preference regarding oral versus injectable administration. The lack of efficacy with select biologics tested—particularly those targeting eosinophils and IL-1 pathways—refines understanding of CSU pathogenesis and should discourage off-label use of these agents.

As additional long-term safety and tolerability data emerge, these agents may shift CSU management paradigms, particularly for the significant proportion of patients for whom traditional approaches prove inadequate.

References

1. Chen J, Ou S, Wu W, Zou H, Li H, Zhu H. Omalizumab in chronic spontaneous urticaria: a real-world study on effectiveness, safety and predictors of treatment outcome. Clin Cosmet Investig Dermatol. 2024;17:1799-1808. Published 2024 Aug 7. doi:10.2147/CCID.S470160
2. Kadu P, Huang CA, Gebara M, et al. Evidence-based review of newer drugs for chronic spontaneous Urticaria. Poster presented at the 2026 American Academy of Dermatology Annual Meeting. Denver, Colorado. March 27-31, 2026. https://eposters.aad.org/s3/AM2026/poster/72240/Evidence-Based+Information+on+Newer+Drugs+for+Chronic+Spontaneous+Urticaria.pdf